Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Use of convalescent plasma inCOVID‐19 patients with immunosuppression
Senefeld, Jonathon W. , Klassen, Stephen A. , Ford, Shane , Senese, Katherine A. , Wiggins, Chad C. , Bostrom, Bruce , Nicholson, Wayne T. , Carter, Rickey E. , Hartman, William R. , Pirofski, Liise‐anne , Wright, R. Scott , Fairweather, De Lisa, Bruno, Katelyn A. , Joyner, Michael J. , Fairweather, DeLisa , Ford, Shane K, Hartman, William R , Fairweather, DeLisa , Carter, Rickey E , Wiggins, Chad C , Joyner, Michael J , Senefeld, Jonathon W , Klassen, Stephen A , Bruno, Katelyn A , Thompson, Michael A. , Baker, Sarah E. , Johnson, Patrick W. , Henderson, Jeffrey P. , Paneth, Nigel , Casadevall, Arturo

Mayo Clinic

Transfusion | May 26, 2021 | Volume: 61 | Issue: 8 | Pages: 2503-2511

10.1111/trf.16525 | PMID 34036587 Get It

AbstractIn the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel coronavirus disease 19 (COVID‐19), including among patients with innate or acquired immunosuppression. However, the association between COVID‐19‐associated mortality in patients with immunosuppression and therapeutic use of convalescent plasma is unknown. We review 75 reports, including one large matched‐control registry study of 143 COVID‐19 patients with hematological malignancies, and 51 case reports and 23 case series representing 238 COVID‐19 patients with immunosuppression. We review clinical features and treatment protocols of COVID‐19 patients with immunosuppression after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. The available data from case reports and case series provide evidence suggesting a mortality benefit and rapid clinical improvement in patients with several forms of immunosuppression following COVID‐19 convalescent plasma transfusion. The utility of convalescent plasma or other forms of antibody therapy in immune‐deficient and immune‐suppressed patients with COVID‐19 warrants further investigation.
Evaluation and Management of Autonomic Dysreflexia and Other Autonomic Dysfunctions: Preventing the Highs and Lows
Linsenmeyer, Todd A. , Beck, Lisa A., Elliott, Stacy , Gorman, Peter H. , Vogel, Lawrence C. , Wecht, Jill M. , Clay, Sarah, Krassioukov, Andrei V. , Kirshblum, Steven

Mayo Clinic

Topics in Spinal Cord Injury Rehabilitation | May 24, 2021 | Volume: 27 | Issue: 2 | Pages: 225-290

10.46292/sci2702-225 | PMID 34108837 Get It

Future Directions in Maintenance Therapy in Multiple Myeloma
Holstein, Sarah A. , Hillengaß, Jens, Suman, Vera J. , Hillengass, Jens, McCarthy, Philip L.

Mayo Clinic

Journal of Clinical Medicine | May 24, 2021 | Volume: 10 | Issue: 11 | Pages: 2261

10.3390/jcm10112261 | PMID 34073689 Get It

Autologous stem cell transplantation (ASCT) has been a backbone of therapy for newly diagnosed patients with multiple myeloma eligible for high-dose therapy for decades. Survival outcomes have continued to improve over time, in part because of the incorporation of highly effective induction regimens prior to ASCT as well as post-ASCT maintenance therapy. Randomized phase III clinical trials have helped establish lenalidomide maintenance as a standard of care. However, as nearly all patients will eventually experience disease relapse, there continues to be significant interest in developing novel maintenance strategies to improve upon lenalidomide maintenance. In this review, we summarize the available evidence for the use of immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies as post-ASCT maintenance therapies as well as discuss future directions and unanswered questions in the field.
Machine-Learning Approach to Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors: A Multicenter Study
Zhang, Michael , Tong, Elizabeth , Hamrick, Forrest , Lee, Edward H. , Tam, Lydia , Pendleton, Courtney , Smith, Brandon W. , Hug, Nicholas F. , Biswal, Sandip , Seekins, Jayne , Mattonen, Sarah A. , Napel, Sandy , Campen, Cynthia , Spinner, Robert J. , Yeom, Kristen W. , Wilson, Thomas J. , Mahan, Mark A

Mayo Clinic

Neurosurgery | May 19, 2021 | Volume: 89 | Issue: 3 | Pages: 509-517

10.1093/neuros/nyab212 | PMID 34131749 Get It

Abstract BACKGROUND Clinicoradiologic differentiation between benign and malignant peripheral nerve sheath tumors (PNSTs) has important management implications. OBJECTIVE To develop and evaluate machine-learning approaches to differentiate benign from malignant PNSTs. METHODS We identified PNSTs treated at 3 institutions and extracted high-dimensional radiomics features from gadolinium-enhanced, T1-weighted magnetic resonance imaging (MRI) sequences. Training and test sets were selected randomly in a 70:30 ratio. A total of 900 image features were automatically extracted using the PyRadiomics package from Quantitative Imaging Feature Pipeline. Clinical data including age, sex, neurogenetic syndrome presence, spontaneous pain, and motor deficit were also incorporated. Features were selected using sparse regression analysis and retained features were further refined by gradient boost modeling to optimize the area under the curve (AUC) for diagnosis. We evaluated the performance of radiomics-based classifiers with and without clinical features and compared performance against human readers. RESULTS A total of 95 malignant and 171 benign PNSTs were included. The final classifier model included 21 imaging and clinical features. Sensitivity, specificity, and AUC of 0.676, 0.882, and 0.845, respectively, were achieved on the test set. Using imaging and clinical features, human experts collectively achieved sensitivity, specificity, and AUC of 0.786, 0.431, and 0.624, respectively. The AUC of the classifier was statistically better than expert humans ( P = .002). Expert humans were not statistically better than the no-information rate, whereas the classifier was ( P = .001). CONCLUSION Radiomics-based machine learning using routine MRI sequences and clinical features can aid in evaluation of PNSTs. Further improvement may be achieved by incorporating additional imaging sequences and clinical variables into future models.
Assessing Biomarkers of Breast Cancer Risk in Underserved Women in a Midwestern County
DeWitt, Marla , Croghan, Ivana T. , Vachon, Celine M. , Thacher, Thomas D., Pont, M, Neal, Lonzetta, Jenkins, Sarah M. , Pruthi, Sandhya , DeWitt, Marla A , Venegas Pont, Marcia R, Vachon, Celine M. , Pont, Marcia R. Venegas, Stan, Daniela

Mayo Clinic

Journal of Primary Care & Community Health | May 19, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211017792 | PMID 34009069 Get It

Objective: The primary aim of this study was to evaluate the feasibility of collecting risk factor information and accessing digitized mammographic data in a medically marginalized population. A secondary aim was to examine the association between vitamin D status and mammographic density. Methods: Breast-screening examinations were provided for age-appropriate patients, and a referral for no-cost screening mammography was offered. Study participants were asked to undergo 25-hydroxyvitamin D testing at mammography and 1-year follow-up. Results: Of 62 women approached, 35 (56%) consented to participate. Of 32 participants who had baseline mammography, the median mammographic density measured by VolparaDensity (Volpara Solutions Limited) was 5.7%. After 1 year, 9 women obtained follow-up mammograms, with a median density of 5.7%. Vitamin D status was measured for 31 participants at baseline and 13 participants in the following year. Insufficient vitamin D status (<30 ng/mL) was noted in 77% at each time point. Mammographic density was not significantly correlated with vitamin D status ( P = .06). Conclusions: On the basis of this small pilot study, vitamin D insufficiency is common in this study population. Owing to the small sample size, an association between vitamin D insufficiency and breast density was not clear. Additional unexpected findings included substantial barriers in initial access to care and longitudinal follow-up in this population. Further study of these issues is needed.
Effectiveness of a Vaping Cessation Text Message Program Among Young Adult e-Cigarette Users
Cha, Sarah , Bottcher, Mia M. , Papandonatos, George D. , Amato, Michael S. , Graham, Amanda L. , Jacobs, Megan A

Mayo Clinic

JAMA Internal Medicine | May 17, 2021 | Volume: 181 | Issue: 7 | Pages: 923

10.1001/jamainternmed.2021.1793 | PMID 33999133 Get It

First Report of Proton Beam Therapy in a Patient With a Left Ventricular Assist Device
Schumer, Erin M. , Schettle, Sarah , Stulak, John M., Rosenbaum, Andrew , Rosenbaum, Andrew N

Mayo Clinic

ASAIO Journal | May 14, 2021 | Volume: 68 | Issue: 5 | Pages: e84-e86

10.1097/mat.0000000000001478 | PMID 35503645 Get It

A 77 year old man previously implanted with a HeartMate II left ventricular assist device (LVAD) as destination therapy and an implantable cardioverter defibrillator presented with a left upper lobe squamous cell lung cancer. Oncology determined that proton beam therapy was indicated for treatment, and a multidisciplinary team of radiation physicists, radiation oncologists, and LVAD providers developed a protocol to proceed safely. He was successfully treated with combined proton beam radiation therapy and reduced dose chemotherapy. This case demonstrates feasibility and considerations of proton beam therapy for malignancy relevant to patients with implantable cardiac devices including LVADs.
Stereotactic Radiosurgery for Differentiated Thyroid Cancer Brain Metastases: An International, Multicenter Study
Fribance, Sarah , Pikis, Stylianos , Lee, John Y. K. , Buch, Love, Bernstein, Kenneth , Mathieu, David , Perron, Rémi, Patel, Samir , Álvarez, Roberto Martínez , Moreno, Nuria Martínez , Lee, Cheng‐Chia , Strickland, Ben A. , Zada, Gabriel , Chang, Eric L. , Kondziolka, Douglas , Sheehan, Jason P. , Mathieu, David , Kondziolka, Douglas , Bunevičius, Adomas , Moran, Michael, Yang, Andrew I. , Liščák, Roman , Šimonová, Gabriela , Trifiletti, Daniel M. , Yang, Huai‐Che

Mayo Clinic

Thyroid® | May 12, 2021 | Volume: 31 | Issue: 8 | Pages: 1244-1252

10.1089/thy.2020.0947 | PMID 33978475 Get It

Background: Brain metastases (BM) from differentiated thyroid cancer are rare. Stereotactic radiosurgery (SRS) is commonly used for the treatment of BMs; however, the experience with SRS for thyroid cancer BMs remains limited. The goal of this international, multi-centered study was to evaluate the efficacy and safety of SRS for thyroid cancer BMs. Methods: From 10 institutions participating in the International Radiosurgery Research Foundation, we pooled patients with established papillary or follicular thyroid cancer diagnosis who underwent SRS for histologically confirmed or radiologically suspected BMs. We investigated patient overall survival (OS), local tumor control, and adverse radiation events (AREs). Results: We studied 42 (52% men) patients who underwent SRS for 122 papillary (83%) or follicular (17%) thyroid cancer BMs. The mean age at SRS was 59.86 ± 12.69 years. The mean latency from thyroid cancer diagnosis to SRS for BMs was 89.05 ± 105.49 months. The median number of BMs per patient was 2 (range: 1–10 BMs). The median SRS treatment volume was 0.79 cm 3 (range: 0.003–38.18 cm 3 ), and the median SRS prescription dose was 20 Gy (range: 8–24 Gy). The median survival after SRS for BMs was 14 months (range: 3–58 months). The OS was significantly shorter in patients harboring ≥2 BMs, when compared with patients with one BM (Log-rank = 5.452, p = 0.02). Two or more BMs (odds ratio [OR] = 3.688; confidence interval [CI]: 1.143–11.904; p = 0.03) and lower Karnofsky performance score at the time of SRS (OR = 0.807; CI: 0.689–0.945; p = 0.008) were associated with shorter OS. During post-SRS imaging follow-up of 25.21 ± 30.49 months, local failure (progression and/or radiation necrosis) of BMs treated with SRS was documented in five (4%) BMs at 7.2 ± 7.3 months after the SRS. At the last imaging follow-up, the majority of patients with available imaging data had stable intracranial disease (33%) or achieved complete (26%) or partial (24%) response. There were no clinical AREs. Post-SRS peritumoral T2/fluid attenuated inversion recovery signal hyperintensity was noted in 7% BMs. Conclusion: The SRS allows durable local control of papillary and follicular thyroid cancer BMs in the vast majority of patients. Higher number of BMs and worse functional status at the time of SRS are associated with shorter OS in patients with thyroid cancer BMs. The SRS is safe and is associated with a low risk of AREs.
Climate change, human migration, and skin disease: is there a link?
Sugiharto, Audi , Coates, Sarah J. , Lucero‐Prisno, Don Eliseo , Davis, Mark Denis D., Andersen, Louise K. , Sugiharto, Audi , Coates, Sarah J , Lucero-Prisno, Don Eliseo , Andersen, Louise K , Dayrit, Johannes F.

Mayo Clinic

International Journal of Dermatology | May 10, 2021 | Volume: 61 | Issue: 2 | Pages: 127-138

10.1111/ijd.15543 | PMID 33971021 Get It

Abstract Climate change, exemplified by higher average global temperatures resulting in more frequent extreme weather events, has the potential to significantly impact human migration patterns and health. The consequences of environmental catastrophes further destabilize regions with pre‐existing states of conflict due to social, political, and/or economic unrest. Migrants may carry diseases from their place of origin to their destinations and once there may be susceptible to diseases in which they had not been previously exposed to. Skin diseases are among the most commonly observed health conditions observed in migrant populations. To improve awareness among dermatologists of the burden of skin diseases among migrants, the group searched the English language scientific literature to identify articles linking climate change, migration, and skin disease. Skin diseases associated with human migration fall into three major categories: (i) communicable diseases, (ii) noncommunicable diseases, and (iii) environmentally mediated diseases. Adopting comprehensive global strategies to improve the health of migrants requires urgent attention.